| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.59 | 0.00 (0.00%) | 11.73 - 16.87 | 308.6 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 14.50 |
|---|---|
| Previous Close | 14.59 |
| Day's Range | 14.41 - 14.66 |
| Market Cap | 1.4B |
| Avg Volume (10 Day) | 485.3K |
| Price/Earnings (Trailing 12 Mo.) | 37.4x |
| Earnings Per Share (Trailing 12 Mo.) | 0.39 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Akorn Reports First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 6:00 AM ET
| AKRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 70.53% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.57 | |
| LT Debt/Equity | 0.57 | |
| Earnings Yield | 2.67% | |
| Price/Sales | 5.04 |
| Company | Last | Change |
|---|---|---|
| Momenta Pharmaceuticals Inc | 13.39 | +0.60% |
| Ligand Pharmaceuticals Inc | 27.47 | -1.72% |
| Sagent Pharmaceuticals Inc | 17.75 | -0.78% |
| Avanir Pharmaceuticals Inc | 3.41 | +0.29% |
| Hi-Tech Pharmacal Co Inc | 33.70 | -1.98% |
Data is delayed by at least 15 min.